Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Open Access
- 18 April 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 5 (5), 691-706
- https://doi.org/10.1002/emmm.201202176
Abstract
A recently proposed therapeutic approach for lysosomal storage disorders (LSDs) relies upon the ability of transcription factor EB (TFEB) to stimulate autophagy and induce lysosomal exocytosis leading to cellular clearance. This approach is particularly attractive in glycogen storage disease type II [a severe metabolic myopathy, Pompe disease (PD)] as the currently available therapy, replacement of the missing enzyme acid alpha‐glucosidase, fails to reverse skeletal muscle pathology. PD, a paradigm for LSDs, is characterized by both lysosomal abnormality and dysfunctional autophagy. Here, we show that TFEB is a viable therapeutic target in PD: overexpression of TFEB in a new muscle cell culture system and in mouse models of the disease reduced glycogen load and lysosomal size, improved autophagosome processing, and alleviated excessive accumulation of autophagic vacuoles. Unexpectedly, the exocytosed vesicles were labelled with lysosomal and autophagosomal membrane markers, suggesting that TFEB induces exocytosis of autophagolysosomes. Furthermore, the effects of TFEB were almost abrogated in the setting of genetically suppressed autophagy, supporting the role of autophagy in TFEB‐mediated cellular clearance.This publication has 68 references indexed in Scilit:
- β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe diseaseMolecular Genetics and Metabolism, 2012
- Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgottenSeminars in Medical Genetics, Part C of the American Journal of Medical Genetics, 2012
- Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular ClearanceDevelopmental Cell, 2011
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- Mammalian autophagy: core molecular machinery and signaling regulationCurrent Opinion in Cell Biology, 2010
- Murine muscle cell models for Pompe disease and their use in studying therapeutic approachesMolecular Genetics and Metabolism, 2009
- Chapter 21 Monitoring Autophagy in Lysosomal Storage DisordersMethods in Enzymology, 2009
- Therapeutic approaches in glycogen storage disease type II/pompe diseaseNeurotherapeutics, 2008
- Neuraminidase 1 Is a Negative Regulator of Lysosomal ExocytosisDevelopmental Cell, 2008
- Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe DiseaseMolecular Therapy, 2006